Ryan Billings – Senior Director, Digital Innovation
As Senior Director, Digital Innovation at AMAG Pharmaceuticals, Ryan is responsible for advancing modern marketing capabilities, solving business problems through innovative pilot programs, increasing internal digital acumen, and forming strategic digital partnerships. Prior to joining AMAG, Ryan led Social Strategy at both Merck and AstraZeneca. Ryan has pioneered digital standards across the industry, including the launches of the first branded Rx social communities with open comments, the first mobile co-pay cards, award-winning medical student ambassador blogs, and an internal social media insights program.
Irene is the Director of Drug Discovery at Verge Genomics in San Francisco, CA. She has spent her career in early drug discovery in neuroscience and oncology having led multiple programs, one of which was of a novel opioid analgesic with demonstrated efficacy in Phase 3 clinical trials. At Verge Genomics, she works with biologists and computational scientists to test artificial intelligence enabled machine learning predictions at the bench to identify novel therapeutics in neurodegenerative diseases.
Senior Vice President of Product Marketing
SAAMA TECHNOLOGIES INC.
Karim Damji – Senior Vice President of Product Marketing
SAAMA TECHNOLOGIES INC.
Karim Damji is responsible for product management, marketing, and solution development at Saama Technologies.
Karim joined Saama from Plantronics, where he led software strategy and product management, focusing on driving developer platforms, strategic partner integrations and contextually enabled UC solutions. Prior to joining Plantronics, Karim served in leadership positions spanning business development, product management, sales and network engineering at Cisco, Vocera Communications, MobileIron, and DiVitas. Karim spent 7 years at Cisco building global VoIP and WAN networks, eventually transitioning to product architecture positions. At Vocera Communications and DiVitas, Karim was the founding head of products responsible for driving product concept to market-leading solutions.
Karim has served as a founder and strategic advisor to early-stage startups and is currently involved in mission-driven startups and IoT open-source communities. Karim studied computational and applied mathematics at San Jose State University.
Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing BioEngine4D to digitally detect developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working as a healthcare investment banker with hundreds of innovators. From Analyst through Managing Director, Savan led 40 deals, totaling $35 billion, across the drug, diagnostic, and device spectrum. Savan began his career as a little bioengineer in a big lab at Life Technologies.
Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania.
A deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer – which compelled asking “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.
Associate Director Materials and Innovation
Ronald Dorenbos – Associate Director Materials and Innovation
As Associate Director of Materials & Innovation and as a member of Takeda’s Digital Strategy team for Neuroscience Ronald helps Takeda with its technology and innovation strategy, identifying technologies that can benefit Takeda’s core areas Oncology, Neuroscience and Gastroenterology. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization, and digital health and at his company BioFrontline he provided management, strategy and commercial advice to life sciences companies around the world. After obtaining MAs in Biotechnology and Molecular Biology and a Ph.D. in Pharmaceutical Biology he spent six years at Harvard studying Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of applications of AI and deep learning in pharma and healthcare and is the founder of the LinkedIn group 'AI – Artificial Intelligence.'
Professor, Departments of Medicine and Cell and Molecular Medicine
UC SAN DIEGO
Pradipta Ghosh – Professor, Departments of Medicine and Cell and Molecular Medicine
UC SAN DIEGO
Dr. Ghosh is a physician-scientist with dual training in internal medicine and basic science. She is the founding Director of the Center for Network Medicine (UCSD). A multidisciplinary team at the CNM continues to strive towards a goal of understanding the fundamental principles that allow eukaryotic cells to do their business, i.e., iteratively sense, decide, act and learn/adapt. The central hypothesis is that cells do so through an ad hoc molecular interaction network whose architectural principles and computational rules are similar to those used in the layered communication systems in the engineering world. These rules enable noise reduction, error minimization, shielding and encapsulation of breakdowns, control of delays and state explosion, etc. Success in decoding these fundamental rules should not only enable us to complete and ‘clean up’ the existing incomplete and messy biological networks, but also use these network for simulating and predicting cell behavior. This will usher a new era in network-based diagnostic tools and network-resetting therapeutics for major diseases. On the flip side, knowing how a cell autonomously carries out its business will provide insights into designing new kinds of self-organizing networks (SON) and provide a novel paradigm (beyond artificial neural networks) for developing Artificial Intelligence (AI). She is joined in this mission by Vint Cerf, the Father of the Modern Internet and A.M. Turing Medalist and Mel I. Simon, who co-Chaired with Laureate Al. Gilman the decade-long initiative, the Alliance for Cell Signaling (AfCS).
Senior Manager A.I./Machine Learning Development
Kevin Hua – Senior Manager A.I./Machine Learning Development
Dr. (Kevin) Hua has 20 years of experience working in design and development of AI/Machine Learning applications in healthcare, insurance, banking, retails and manufacturing industries. He is currently a senior manager with the Digital Health Intelligence Group of Bayer, responsible for developing AI/ML applications. Prior to Bayer, he was a machine learning specialist at Deloitte Consulting and a research manager of AI at Center for Advanced Research of PwC. His work in analytics has won the Analytics Leadership Award from IU Kelley School of Business in 2014 and INFORMS Data Mining contest in 2008.
Christopher Jordan is principally responsible for all aspects of Click’s technology strategy and development, with product, design, engineering, and data science teams reporting into him. Mr. Jordan has over nine years of technology management experience and played a key role as an engineering manager at Bloomberg LP prior to joining Click. Mr. Jordan holds a BSE in Computer Engineering from the University of Michigan.
Rishi Madhok – Chief Executive Officer and Co-Founder
Rishi Madhok, M.D., is a board-certified emergency medicine physician who focuses on bridging the gap between technology and medicine. Prior to founding BitMED, Rishi partnered with the Harvard Humanitarian Initiative, Rishi was the technical lead expert in the development of portable medical software to analyze the health needs of refugee and third world populations.
Rishi’s research has led to significant medical innovations and has been presented both nationally and internationally. Rishi was previously Director of Clinical Informatics at the University of Pennsylvania hospital. He has also been a medical advisor to multiple small and medium stage companies, including Warby Parker, Wellzio, and Good Parents Inc.
Rishi obtained his medical degree at Columbia University College of Physicians and Surgeons and completed his emergency medicine residency training at NewYork-Presbyterian Hospital — the University Hospital of Columbia & Cornell. Rishi was among the earliest physicians to become board certified in the emerging field of Clinical Informatics.
, MBA, Ph.D.
Senior Director, Head of Digital Health Care Initiatives
SUNOVION PHARMACEUTICALS INC.
Georgia Mitsi – Senior Director, Head of Digital Health Care Initiatives
SUNOVION PHARMACEUTICALS INC.
Georgia Mitsi, MBA, Ph.D., is Senior Director, Head of Digital Health Care Initiatives at Sunovion, which is focused on the innovative application of science, medicine and technologies to help people with serious psychiatric, neurological and respiratory conditions.
Dr. Mitsi oversees initiatives that focus on integrating digital health technologies into Sunovion’s solutions to contribute towards the goals to significantly to empower patients to better manage their symptoms and improve quality of life for those who are living with chronic medical conditions. She also contributes to Sunovion’s support of public-private partnerships designed to accelerate digital health care solutions.
Dr. Mitsi was named as a 2018 PharmaVOICE 100 inspirational leader, recognized as a digital expert and transformational leader who is moving the industry forward using a variety of digital strategies and tools. She was also recognized by CenterWatch as a Top 20 innovator. Dr. Mitsi is a hands-on digital innovator with expertise in health outcomes and health economics research and experience in pharmaceutical and healthcare industry consulting. Prior to joining Sunovion, Dr. Mitsi was Founder and Chief Executive Officer of Apptomics, which provided scientifically-validated mobile applications. Previously, she served in health economics and clinical research roles at United BioSource Corporation and in health research services at Humana.
Dr. Mitsi is an active blogger on a variety of digital healthcare topics and has authored numerous scientific publications and two novels. She has been a long-time supporter and mentor to digital health start-up companies and has served as a Judge and Mentor as part of the MIT Enterprise Forum. Dr. Mitsi holds an MBA in international business from the University of Miami School of Business Administration, and a Ph.D. in Pharmacoepidemiology and MSc in Applied Medical Sciences from the University of Patras.
Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William Paiva – Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William D. Paiva, Ph.D., is Executive Director of Oklahoma State University’s Center for Health Systems Innovation (CHSI). The Center is focused on transforming rural and Native America health through the implementation of innovative care delivery and IT solutions. Within CHSI, the Institute for Predictive Medicine is applying advanced analytics to the largest health care database which includes clinical information for over 63 million patients covering 16 years.
Prior to joining Oklahoma State University, Dr. Paiva was a partner, joined Sevin Rosen Funds, a fund with over $2 billion under management, where he brought more than 20 years of venture-capital, biomedical-industry and management-consulting experience to the firm. William specialized in identifying early-stage venture opportunities at the intersection of traditional technology sectors and healthcare. He also used his healthcare expertise and network to assist Sevin Rosen portfolio companies developing applications and services for the healthcare market. Prior to Sevin Rosen, William was a partner at Chisholm Private Capital Partners, where he managed a $100 million fund focused on healthcare and IT. He also worked as a manager at the Oklahoma Life Science Fund, managing $15 million and making investments in diagnostics, services and therapeutics firms.
Before that, William served as a management consultant for the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath, later acquired by PriceWaterhouseCoopers, where he consulted with the top five pharmaceutical companies on product-development and technology-management projects. William also served as an investment banking associate at JP Morgan in New York, providing strategic and investment banking advisory services to Fortune 100 healthcare companies.
William holds a Ph.D. in molecular biology from the University of Oklahoma; an MBA from Dartmouth College’s Amos Tuck School of Business; a master’s degree in microbiology and immunology from the University of Oklahoma Health Science Center; and a B.S. in microbiology from the University of Oklahoma.
Aris Persidis is President and co-founder of Biovista. He is responsible for outreach and business development and has helped design the specifications and tracking of the Project Prodigy AI. Aris authored the Industry Trends column for Nature Biotechnology, was a judge for the 2011 Top-10 Innovations of The Scientist and served as the inaugural co-Editor-in-Chief of Drug Rescue, Repurposing and Repositioning. He was SVP, Business Development for Upstate Bio (acquired by Serologicals), Managing Director of Rheogene (acquired by Intrexon), and participated in the cofounding of Cellzome (acquired by GSK), and Anadys (acquired by Roche). Aris was also adjunct assistant professor at Wharton and holds a Ph.D. in biochemistry from Cambridge.
Dr. Kelly Stanton is a bioinformatics expert and visiting scientist at Yale University, applying statistics, signal processing and mathematics to analyze DNA sequencing data since 2010. He earned his B.S. in Biomedical Engineering from the University of Texas at Austin and Ph.D. in Bioinformatics at Yale University in 2015. Kelly has published work ranging from bioinformatics applications to new mathematical techniques for general data science use. His post-doctoral work is focused on pioneering new deep learning based algorithms for unsupervised and semi-supervised learning. Currently, Kelly designs predictive analytics for clinical outcomes based on medical IOT data at Potrero Medical. He currently resides in San Francisco, CA.
Saheel Sutaria is the Chief Technology Officer at Potrero Medical, a Silicon Valley-based startup in predictive health developing the next generation of smart sensors and artificial intelligence.
Saheel has a history of having developed electrical and software systems from the ground up for companies such as Stryker and Minerva Surgical. Most recently, he led R&D and business development for Gravitas, a smart nasogastric feeding system.
Vice President, Digital Health and Business Operations
Charles Wolfus – Vice President, Digital Health and Business Operations
As MyoKardia’s head of Digital Health, Charles Wolfus is on a mission to improve patient lives by applying sensors, social media, mobile technology, and artificial intelligence in clinical trials and daily life.
In 2016, Charles led MyoKardia’s multidisciplinary team in the world’s first use of wearables in an interventional clinical study. MyoKardia’s phase 2 PIONEER-HCM clinical trial used these sensors to capture PPG data as an exploratory endpoint. Through subsequent machine-learning analysis, MyoKardia was able to detect HCM with greater than 95% accuracy.
Charles is a recognized thought leader in the fusion of wearable technology and its use in clinical trials. He passionately believes that these technologies will improve healthcare for all. Charles has been a technology leader in biotech for nearly 20 years and a featured a speaker at international digital health symposia. He is licensed to practice law in the State of California.
Please fill out the form to download the brochure on the AI Innovations For Life Science Summit WestDownload Brochure